2185 — Shanghai Bio-heart Biological Technology Share News
0.000.00%
Last trade - 00:00- HK$267.76m
- HK$407.81m
- CNY44.93m
Brief: Shanghai Bio-Heart Biological Technology Says Iberis Rdn System Completes Registration In Vietnam
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completed Registration In Thailand
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completes Registration With MHRA In UK
Brief: Shanghai Bio-Heart Biological Technology's Controlling Shareholder Increases Shareholding
Brief: Shanghai Bio-Heart Biological Technology Says Investor To Inject RMB155.6 Mln In Zhejiang Bioheart
Brief: Shanghai Bio-Heart Biological Technology Announces Formation Of Limited Partnership
Brief: Shanghai Bio-heart Biological Technology Posts H1 Capex Of RMB19.8 Mln
Brief: Shanghai Bio-Heart Biological Technology Posts Net Loss For Year Rmb188.8 Mln
Brief: Shanghai Bio-Heart Biological Technology Posts HY Loss For Period RMB95.1 Mln
Brief: Shanghai Bio-Heart Biological Technology To Make Capital Increase Of RMB15 Mln Into Shanghai Xinzhi Medical Technology
Brief: Shanghai Bio-Heart Biological Technology Posts FY Loss Attributable Of RMB204.2 Mln
Brief: Shanghai Bio-Heart Biological Technology Says Completion Of Conversion And Listing Of Domestic Shares
Brief: Shanghai Bio-Heart Biological Technology Says Approval For Listing Of=As-Converted Shares Granted
Brief: Shanghai Bio-Heart Biological Technology Sees Drug Approval For Urgent Clinical Use
Brief: Shanghai Bio-Heart Biological Technology Says Trial Of Sirolimus Be In Japan
Brief: Shanghai Bio-Heart Biological Technology Receives Approval From China Securities Regulatory Commission
Brief: Shanghai Bio-Heart Biological Technology To Make Capital Injection Into Cardiotek (Beijing)
Brief: Shanghai Bio-Heart Biological Technology Proposed Issue Of A Shares & Listing On Sci-Tech Board Of Shanghai Stock Exchange
Brief: Shanghai Bio-Heart Biological Technology - Achieves Pre-Set Primary Clinical Endpoint- In Rct Of Bioheart-Ii